Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Tacrolimus in the prevention of adverse pregnancy outcomes and diabetes-associated embryopathies in obese and diabetic mice

Authors: Ahmad J. H. Albaghdadi, Melanie A. Hewitt, Samantha M. Putos, Michael Wells, Terence R. S. Ozolinš, Frederick W. K. Kan

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

T2DM is a high-risk pregnancy with adverse fetal and maternal outcomes including repeated miscarriages and fetal malformations. Despite the established association between placental insufficiency and poor maternal Th1-adaptability to the development of pregnancy complications in T2DM, there have been no established data to assess benefits of pre-pregnancy immunosuppression relative to gestational outcomes in T2DM. We hypothesized that pre-pregnancy macrolide immune suppression can re-establish normal placental development and uterine vascular adaptation in a mouse model of obesity-associated T2DM.

Methods

Fetal live birth rate, postnatal variability, mid-gestational uterine and umbilical flow dynamics and certain morphological features of spiral artery modification were examined in the New Zealand Obese (NONcNZO10/Ltj) female mice (n = 56) weaned to ages of 32 weeks on a 60% calories/g high-fat diet (also referred to as HFD-dNONcNZO), and which received either tacrolimus (0.1 mg/kg s.c. q2d) , its vehicle (castor oil and ethanol) or metformin (in drinking water 200 mg/dL p.o. ad libitum). HFD-BALBc-Rag2/IL2-gc female mice (n = 24) were used as HFD-immunodeficient controls.

Results

Treatment of the HFD-dNONcNZO female mice with tacrolimus improved live birth rates and postnatal viability scores (p < 0.01), normalized OGTT (p < 0.001), inhibited fetal malformation rates, restored morphology of spiral arterial modification; and improved uterine arterial and umbilical blood flow (p < 0.01). Placental production of TNFαand IL16 in the tacrolimus-treated HFD-dNONcNZO dams were restored to non-diabetic levels and the treatment resulted in the inhibition of aberrant monocyte/macrophage activation during pregnancy in the HFD-dNONcNZO dams.

Conclusions

Our present data suggest a casual association between chronic maternal overnutrition and aberrancy in the maternal Th1-immune maladaptation to pregnancy and defective spiral artery modification, placental insufficiency and adverse fetal outcomes in the T2DM subjects. Further safety studies into the use of tacrolimus in the pre-pregnancy glycemic control may be beneficial.
Appendix
Available only for authorised users
Literature
1.
Catalano PM, Ehrenberg HM. The short- and long-term implications of maternal obesity on the mother and her offspring. BJOG. 2006;113(10):1126–33.CrossRefPubMed
2.
Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–76.CrossRefPubMed
3.
Casson IF, Clarke CA, Howard CV, McKendrick O, Pennycook S, Pharoah PO, et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ. 1997;315(7103):275–8.CrossRefPubMedPubMedCentral
4.
Platt MJ, Stanisstreet M, Casson IF, Howard CV, Walkinshaw S, Pennycook S, et al. St Vincent’s declaration 10 years on: outcomes of diabetic pregnancies. Diabet Med. 2002;19(3):216–20.CrossRefPubMed
5.
Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477–86.CrossRefPubMed
6.
Owens LA, Sedar J, Carmody L, Dunne F. Comparing type 1 and type 2 diabetes in pregnancy-similar conditions or is a separate approach required? BMC Pregnancy Childbirth. 2015;15:69.CrossRefPubMedPubMedCentral
7.
Leiter EH, Reifsnyder PC, Flurkey K, Partke H-J, Junger E, Herberg L. NIDDM genes in mice: deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes. 1998;47(8):1287–95.CrossRefPubMed
8.
Leiter EH, Reifsnyder PC. Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes. 2004;53(Suppl 1):S4–11.CrossRefPubMed
9.
Radavelli-Bagatini S, Blair AR, Proietto J, Spritzer PM, Andrikopoulos S. The New Zealand obese mouse model of obesity insulin resistance and poor breeding performance: evaluation of ovarian structure and function. J Endocrinol. 2011;209(3):307–15.CrossRefPubMed
10.
Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years. Transplantation. 2003;76(5):827–32.CrossRefPubMedPubMedCentral
11.
Westbrook RH, Yeoman AD, Agarwal K, Aluvihare V, O’Grady J, Heaton N, et al. Outcomes of pregnancy following liver transplantation: the King’s College Hospital experience. Liver Transpl. 2015;21(9):1153–9.CrossRefPubMed
12.
13.
Miyamoto T, Li Z, Kibushi T, Okano S, Yamasaki N, Kasai N. Utility of recycled bedding for laboratory rodents. J Am Assoc Lab Anim Sci. 2009;48(4):405–11.PubMedPubMedCentral
14.
Wimer RE, Fuller JL. Patterns of behavior. In: Green EL, editor. Biology of the laboratory mouse. New York: McGraw-Hill; 1966. p. 629–53.
15.
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15–26.CrossRefPubMed
16.
17.
Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Investig. 2010;120(7):2355–69.CrossRefPubMedPubMedCentral
18.
Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet. 2002;32(6):435–43.CrossRefPubMedPubMedCentral
19.
Mu J, Adamson SL. Developmental changes in hemodynamics of uterine artery, utero- and umbilicoplacental, and vitelline circulations in mouse throughout gestation. Am J Physiol Heart Circ Physiol. 2006;291(3):H1421–8.CrossRefPubMed
20.
Acharya G, Wilsgaard T, Berntsen GKR, Maltau JM, Kiserud T. Reference ranges for serial measurements of blood velocity and pulsatility index at the intra-abdominal portion, and fetal and placental ends of the umbilical artery. Ultrasound Obstet Gynecol. 2005;26(2):162–9.CrossRefPubMed
21.
Stuckhardt JL, Poppe SM. Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. Teratog Carcinog Mutagen. 1984;4(2):181–8.CrossRefPubMed
22.
Kimmel CA, Trammell C. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol. 1981;56(5):271–3.CrossRefPubMed
23.
Makris SL, Solomon HM, Clark R, Shiota K, Barbellion S, Buschmann J, et al. Terminology of developmental abnormalities in common laboratory mammals (version 2). Congenit Anom. 2009;49(3):123–246.CrossRef
24.
Mikel U. Advanced laboratory methods in histology and pathology. In: Mikel UV, editor. Advanced laboratory methods in histology and pathology. Washington: Armed Forces Institute of Pathology, American Registry of Pathology; 1994. p. 161–207.
25.
Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008;295(6):E1323–32.CrossRefPubMed
26.
Garcia-Patterson A, Aulinas A, Maria MA, Ubeda J, Orellana I, Ginovart G, et al. Maternal body mass index is a predictor of neonatal hypoglycemia in gestational diabetes mellitus. J Clin Endocrinol Metab. 2012;97(5):1623–8.CrossRefPubMed
27.
Chen JR, Zhang J, Lazarenko OP, Kang P, Blackburn ML, Ronis MJJ, et al. Inhibition of fetal bone development through epigenetic down-regulation of HoxA10 in obese rats fed high-fat diet. FASEB J. 2012;26(3):1131–41.CrossRefPubMed
28.
Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013;95(7):908–15.CrossRefPubMedPubMedCentral
29.
Akturk S, Celebi ZK, Erdogmus S, Kanmaz AG, Yuce T, Sengul S, et al. Pregnancy after kidney transplantation: outcomes, tacrolimus doses, and trough levels. Transplant Proc. 2015;47(5):1442–4.CrossRefPubMed
30.
Saegusa T, Ohara K, Noguchi H, York RG, Weisenburger WP, Sahardein JL. Reproductive and developmental studies of tacrolimus (FK506) in rats and rabbits. Clin Rep. 1992;26:969–81.
31.
DE Farley SJ, Alexander D, Scott JR. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. Transplantation. 1991;52:106–10.CrossRefPubMed
32.
Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2008:89–105.
33.
Jain A, Marcos A, Reyes J, Mazariagos G, Kashyap R, Eghtesad B, et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc. 2005;37(2):1207–10.CrossRefPubMed
34.
Armenti V, Coscia L, McGrory C, Moritz M. National transplantation pregnancy registry looks at outcomes with neoral and tacrolimus. Nephrol News Issues. 2000;14(9):S11.PubMed
35.
Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13(Suppl 1):S299–300.CrossRefPubMed
36.
Ramos AF, Rodrigues JK, da Silva LR, Guerra Mde O, Peters VM. Embryo development in rats treated with tacrolimus during the preimplantation phase. Rev Bras Ginecol Obstet. 2008;30(5):219–23.CrossRefPubMed
37.
Wu Z, Meng Q, Xia Y, Zhang F, You W. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients. J Biomed Res. 2013;27(4):305–9.CrossRefPubMedPubMedCentral
38.
Omoto K, Tanabe K, Tokumoto T, Ishida H, Shimmura H, Makiyama K, et al. Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience. Transplant Proc. 2002;34(5):1821–2.CrossRefPubMed
39.
Zheng S, Easterling TR, Hays K, Umans JG, Miodovnik M, Clark S, et al. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. Br J Clin Pharmacol. 2013;76(6):988–96.CrossRefPubMedPubMedCentral
40.
Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70(12):1718–21.CrossRefPubMed
41.
Gutierrez MJ, Acebedo-Ribo M, Garcia-Donaire JA, Manzanera MJ, Molina A, Gonzalez E, et al. Pregnancy in renal transplant recipients. Transplant Proc. 2005;37(9):3721–2.CrossRefPubMed
42.
Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64(4):559–65.CrossRefPubMedPubMedCentral
43.
Cotovio P, Neves M, Rodrigues L, Alves R, Bastos M, Baptista C, et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. Transplant Proc. 2013;45(3):1079–83.CrossRefPubMed
44.
Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin N Am. 2007;36(4):873–90.CrossRef
45.
Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):583–95.CrossRefPubMed
46.
Diaz-Garcia C, Johannesson L, Shao R, Bilig H, Brannstrom M. Pregnancy after allogeneic uterus transplantation in the rat: perinatal outcome and growth trajectory. Fertil Steril. 2014;102(6):1545–1552.e1.CrossRefPubMed
47.
Mucha K, Foroncewicz B, Paczek L, Pazik J, Lewandowska D, Krawczyk A, et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. Transplant Proc. 2003;35(6):2176–8.CrossRefPubMed
48.
Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27(9–10):939–58.CrossRefPubMed
49.
Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69(1):1–7.CrossRefPubMed
50.
Evers IM, Nikkels PG, Sikkema JM, Visser GH. Placental pathology in women with type 1 diabetes and in a control group with normal and large-for-gestational-age infants. Placenta. 2003;24(8–9):819–25.CrossRefPubMed
51.
Mayhew T. Enhanced fetoplacental angiogenesis in pre-gestational diabetes mellitus: the extra growth is exclusively longitudinal and not accompanied by microvascular remodelling. Diabetologia. 2002;45:1434–9.CrossRefPubMed
52.
Frias AE, Morgan TK, Evans AE, Rasanen J, Oh KY, Thornburg KL, et al. Maternal high-fat diet disturbs uteroplacental hemodynamics and increases the frequency of stillbirth in a nonhuman primate model of excess nutrition. Endocrinology. 2011;152(6):2456–64.CrossRefPubMedPubMedCentral
53.
Challier JC, Basu S, Bintein T, Minium J, Hotmire K, Catalano PM, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta. 2008;29(3):274–81.CrossRefPubMedPubMedCentral
54.
Wood MM, Romine LE, Lee YK, Richman KM, O’Boyle MK, Paz DA, et al. Spectral Doppler signature waveforms in ultrasonography a review of normal and abnormal waveforms. Ultrasound Q. 2010;26(2):83–99.CrossRefPubMed
55.
Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92(11):4352–8.CrossRefPubMed
56.
Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab. 2008;10(1):53–63.PubMed
57.
Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol. 2006;17(11):3093–104.CrossRefPubMed
58.
Pugliese G, Tilton RG, Williamson JR. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev. 1991;7(1):35–59.CrossRefPubMed
59.
Wautier J, Guillausseau P. Advanced glycation end products, their receptors and diabetic angiopathy. J Peripher Nerv Syst. 2002;7(2):138.CrossRef
60.
Galan HL, Anthony RV, Rigano S, Parker TA, de Vrijer B, Ferrazzi E, et al. Fetal hypertension, and abnormal Doppler velocimetry in an ovine model of intrauterine growth restriction. Am J Obstet Gynecol. 2005;192(1):272–9.CrossRefPubMed
61.
Acharya G, Erkinaro T, Makikallio K, Lappalainen T, Rasanen J. Relationships among Doppler-derived umbilical artery absolute velocities, cardiac function, and placental volume blood flow and resistance in fetal sheep. Am J Physiol Heart Circ Physiol. 2004;286(4):H1266–72.CrossRefPubMed
62.
Leach L, Gray C, Staton S, Babawale MO, Gruchy A, Foster C, et al. Vascular endothelial cadherin and beta-catenin in human fetoplacental vessels of pregnancies complicated by Type 1 diabetes: associations with angiogenesis and perturbed barrier function. Diabetologia. 2004;47(4):695–709.CrossRefPubMed
63.
Ericsson A, Saljo K, Sjostrand E, Jansson N, Prasad PD, Powell TL, et al. Brief hyperglycaemia in the early pregnant rat increases fetal weight at term by stimulating placental growth and affecting placental nutrient transport. J Physiol. 2007;581(3):1323–32.CrossRefPubMedPubMedCentral
64.
Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab. 2002;87(9):4231–7.CrossRefPubMed
65.
Kidokoro K, Satoh M, Nagasu H, Sakuta T, Kuwabara A, Yorimitsu D, et al. Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change. Kidney Blood Press Res. 2012;35(6):549–57.CrossRefPubMed
66.
de Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DR. The CYP3A4*22 C> T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J. 2015;15(2):144–52.CrossRefPubMed
Metadata
Title
Tacrolimus in the prevention of adverse pregnancy outcomes and diabetes-associated embryopathies in obese and diabetic mice
Authors
Ahmad J. H. Albaghdadi
Melanie A. Hewitt
Samantha M. Putos
Michael Wells
Terence R. S. Ozolinš
Frederick W. K. Kan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1137-4

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue

Commentary

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?

Research

R-100 improves pulmonary function and systemic fluid balance in sheep with combined smoke-inhalation injury and Pseudomonas aeruginosa sepsis

Research

Novel neuro-audiological findings and further evidence for TWNK involvement in Perrault syndrome

Research

Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts

Research

Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning

Research

High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits